Where the Comment is King

THE NEWS COMMENTER

VOTE  (0)  (0)

Pfizer and BioNTech begin testing an omicron-specific COVID-19 vaccine

Added 01-25-22 10:07:01am EST - “Though people who are vaccinated and boosted appear to be better protected against omicron, the highly contagious variant has still led to breakthrough cases and a surge in infections worldwide.” - Npr.org

CLICK TO SHARE

Posted By TheNewsCommenter: From Npr.org: “Pfizer and BioNTech begin testing an omicron-specific COVID-19 vaccine”. Below is an excerpt from the article.

Pfizer's logo is shown on the company's production plant in Puurs, Belgium, on Dec. 23, 2020. Jonas Roosens/Belga Mag/AFP via Getty Images hide caption

Pfizer and BioNTech have begun a clinical trial to evaluate a new, omicron-specific vaccine for COVID-19, the pharmaceutical companies announced on Tuesday.

Though people who are vaccinated and boosted appear to be better protected against severe disease and hospitalization from omicron, the highly contagious variant has still led to breakthrough cases and a surge in overall infections across the world.

"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Kathrin U. Jansen, Pfizer's senior vice president and head of vaccine research and development, said in a statement.

One group includes people who have already received two doses of the current Pfizer-BioNTech vaccine and will also receive the omicron vaccine. Another includes those with three doses of the current Pfizer vaccine who will also get the omicron vaccine. The third group includes unvaccinated people who will receive three shots of the omicron vaccine.

Read more...

If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.

Comment Box is loading comments...

CLICK TO SHARE

BACK TO THE HOME-PAGE